Cipla Limited

18%

important to only rely on the advice of a health care professional. 2 Q1FY24 : Revenue up YoY by 18%; Margin expansion YoY by 230+ bps Stellar Performance across all markets KEY HIGHLIGHTS Global Re

INR 6,329

lar Performance across all markets KEY HIGHLIGHTS Global Revenue EBITDA Margin R&D Investment1 INR 6,329 Cr 18% Reported YoY growth 23.6% 233 bps (YoY) 31% Reported YoY growth 5.5% of overall rev

23.6%

IGHLIGHTS Global Revenue EBITDA Margin R&D Investment1 INR 6,329 Cr 18% Reported YoY growth 23.6% 233 bps (YoY) 31% Reported YoY growth 5.5% of overall revenue 27% YoY growth BUSINESS PERF

233 bps

TS Global Revenue EBITDA Margin R&D Investment1 INR 6,329 Cr 18% Reported YoY growth 23.6% 233 bps (YoY) 31% Reported YoY growth 5.5% of overall revenue 27% YoY growth BUSINESS PERFORMANCE

31%

nue EBITDA Margin R&D Investment1 INR 6,329 Cr 18% Reported YoY growth 23.6% 233 bps (YoY) 31% Reported YoY growth 5.5% of overall revenue 27% YoY growth BUSINESS PERFORMANCE One-India

5.5%

estment1 INR 6,329 Cr 18% Reported YoY growth 23.6% 233 bps (YoY) 31% Reported YoY growth 5.5% of overall revenue 27% YoY growth BUSINESS PERFORMANCE One-India North America South Africa

27%

% Reported YoY growth 23.6% 233 bps (YoY) 31% Reported YoY growth 5.5% of overall revenue 27% YoY growth BUSINESS PERFORMANCE One-India North America South Africa Private Market Internat

INR 2,772

USINESS PERFORMANCE One-India North America South Africa Private Market International Markets INR 2,772 Cr 12% $ 222 Mn 43% ZAR 939 Mn 13% $ 95 Mn 2% YoY growth in INR terms YoY growth in $ terms

12%

MANCE One-India North America South Africa Private Market International Markets INR 2,772 Cr 12% $ 222 Mn 43% ZAR 939 Mn 13% $ 95 Mn 2% YoY growth in INR terms YoY growth in $ terms YoY g

43%

a North America South Africa Private Market International Markets INR 2,772 Cr 12% $ 222 Mn 43% ZAR 939 Mn 13% $ 95 Mn 2% YoY growth in INR terms YoY growth in $ terms YoY growth in ZAR Te

13%

South Africa Private Market International Markets INR 2,772 Cr 12% $ 222 Mn 43% ZAR 939 Mn 13% $ 95 Mn 2% YoY growth in INR terms YoY growth in $ terms YoY growth in ZAR Terms YoY growth i

2%

Private Market International Markets INR 2,772 Cr 12% $ 222 Mn 43% ZAR 939 Mn 13% $ 95 Mn 2% YoY growth in INR terms YoY growth in $ terms YoY growth in ZAR Terms YoY growth in $ terms Ma

Notes

1

Conclave

1

Registered Office

1

Notes

1. Market data as per IQVIA MAT June 2023 2. For Anti-diabetic, Jan-23 to Mar-23 is adjusted for Galvus 7 Global consumer wellness franchise : Enhance business and improve health 16% Q1 YoY franchise growth One India Pain relief Hydration INR 75+ Cr INR 65+ Cr Consumer brands in India INR 385 Cr INR 385 Cr 16% Q1 YoY franchise growth SA OTC Cough, cold & flu Cough, cold & flu ZAR 40+ Mn ZAR ~40 Mn Nicotine Replacement Skin infection INR 45+ Cr INR 141C`r INR 30+ Cr Consumer brands in South Africa ZAR 330 Mn Immune Support Gastrointestinal ZAR ~20 Mn ZAR 15+ Mn Cold and cough INR 20+ Cr 8.4% Share of Consumer business in Cipla for Q1 FY24 Respi OTC ZAR 15+ Mn 8 North America: Consistent quarter on quarter growth resulting from strong execution on new launches and traction in base business 13th consecutive quarter of growth in revenue over previous year Lanreotide inj. Launch Lenalidomide launch $ Mn 10% 150 160 155 179 141 142 43% 195 222 204 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3

Conclave

• Cipla ranked 1st amongst the most sustainable companies in Pharma and Healthcare Sector. 91% of total waste recovered, sent to authorized recyclers for reuse or recycling Companies 2022-23. • Cipla ranked 5th amongst the Top 50 India most sustainable 14 Profit and Loss statement summary Particulars Revenue from sale of products Other operating income Income from operations Material cost Employee benefits expense Other expenses Total expenses Finance costs Depreciation, impairment and amortisation expense Other income Profit before tax Tax expenses Share of associate Profit for the period Non-controlling interest Profit for the period attributable to Shareholders Q1 FY24 (INR Cr) 6,269 Q1 FY23 (INR Cr) 5,318 60 6,329 2,237 1,067 1,532 4,835 16 239 136 1,375 378 2 998 2 996 57 5,375 2,024 956 1,252 4,232 18 254 103 975 268 -0 706 20 686 Note : Figures have been rounded-off 15 Thank You

Registered Office

Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Ajinkya Pandharkar Investor.Relations@cipla.com Diksha Maheshwari Investor.Relations@cipla.com For more information please visit www.cipla.com 16